Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

10 Feb 2014

Chinese and American researchers introduce new approach to gene therapy

Resistance of tumor cells toward multiple cytostatic drugs is a serious problem in cancer treatment. In the journal Angewandte Chemie, a team of Chinese and American researchers has now introduced a new approach to gene therapy that could counter this problem: The gene that codes for resistance is “silenced” through the use of an ingenious nanocomplex.

22 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

...

22 Nov 2013

Study uncovers novel mechanism that helps govern regulated gene expression

A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology.

13 Nov 2013

Agilent collaborates with Baylor College of Medicine to provide CGH microarrays to researchers

Agilent Technologies Inc. has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable advanced discoveries in cancer and cytogenetics research.

12 Nov 2013

Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

A team of scientists led by researchers from the University of California, San Diego School of Medicine and Ludwig Institute for Cancer Research have identified a novel therapeutic approach for the most frequent genetic cause of ALS, a disorder of the regions of the brain and spinal cord that control voluntary muscle movement, and frontal temporal degeneration, the second most frequent dementia.

10 Nov 2013

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr Zinc Finger Nuclease technology.

3 Sep 2013

Novel machine learning-based approach used to predict hepatotoxic potential of DNA drug

New classes of therapeutic antisense oligonucleotides can have toxic effects on the liver. A novel machine learning-based approach used to predict the hepatotoxic potential of an antisense drug based on its chemical sequence is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

28 Aug 2013

Sigma Life Science releases genome editing tool for screening and exploratory studies

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, released Sigma CRISPRs, an inexpensive mammalian genome editing tool suitable for screening and exploratory studies.

27 Aug 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

Study suggests modulation of "enhancer-directed RNAs" can alter gene expression in living cells

In a pair of distinct but complementary papers, researchers at the University of California, San Diego School of Medicine and colleagues illuminate the functional importance of a relatively new class of RNA molecules.

5 Jun 2013

Novel technique for manufacturing short, single-stranded DNA molecules

A new method of manufacturing short, single-stranded DNA molecules can solve many of the problems associated with current production methods. The new method, which is described in the scientific periodical Nature Methods, can be of value to both DNA nanotechnology and the development of drugs consisting of DNA fragments.

3 Jun 2013

Safer, more effective treatment option for ovarian cancer

A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer.

31 May 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

25 Feb 2013

Non-coding RNA MALAT1 influences lung cancer metastasis

The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

6 Feb 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Oligonucleotides News and Research

Further Reading

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

Scientists develop new approach to design drugs from genome sequence

Chinese and American researchers introduce new approach to gene therapy

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

Study uncovers novel mechanism that helps govern regulated gene expression

Agilent collaborates with Baylor College of Medicine to provide CGH microarrays to researchers

Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Novel machine learning-based approach used to predict hepatotoxic potential of DNA drug

Sigma Life Science releases genome editing tool for screening and exploratory studies

Technique for developing more targeted drugs using molecular "robots"

Study suggests modulation of "enhancer-directed RNAs" can alter gene expression in living cells

Novel technique for manufacturing short, single-stranded DNA molecules

Safer, more effective treatment option for ovarian cancer

Clinical trial signals new era in treatment of neurodegererative disorders

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

Non-coding RNA MALAT1 influences lung cancer metastasis

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Biochemistry eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics